Prosonix Appoints Respiratory Drug Development Expert Dr Geoff Down as Chief Medical Officer
Prosonix announced the appointment of Dr Geoff Down to the newly created role of Chief Medical Officer. Dr Down takes up his position immediately and will oversee the clinical development of Prosonix’s product pipeline, including PSX1001, PSX1002 and the novel PSX2000 combination series.
Dr Down has more than 18 years’ clinical development experience in the pharmaceutical sector, following ten years in clinical practice in a range of hospital specialties. He joins Prosonix after a successful period running his own company, providing services as a consultant pharmaceutical physician. During this period he worked in clinical safety for Pfizer R&D, in clinical development for RespiVert Ltd (a spinout from Imperial Innovations that aims to identify new treatments for COPD, cystic fibrosis and severe asthma), and since December 2010 he has been working in clinical pharmacology at GlaxoSmithKline’s R&D Respiratory and Immuno-Inflammation medicines development centre (GSK RII MDC).
Dr Down worked in a permanent role at GSK RII MDC from 2002 to 2007, as Director Clinical Pharmacology and Discovery Medicine. In this position, he managed global clinical development programmes and post-licensing support, including significant contributions to the progression of two significant programmes through to global marketing licence submissions [Ariflo (oral cilomilast for COPD) and Avamys/Veramyst (inhaled fluticasone furoate for allergic rhinitis]. He has also held senior roles at Johnson & Johnson Pharmaceutical R&D, ASTA Medica/Baxter and Rhône-Poulenc Rorer.
Dr Down has been a principal investigator or company sponsor for more than 50 early clinical development studies, including first-in-human studies, and over 30 full clinical development trials. He has authored and co-authored several papers, principally in the respiratory field, and presented on a range of regulatory and clinical development topics. He is a Fellow and Senior Specialist Adviser at the Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians (UK).
Other news from the department people
